Biz Break: Gilead's New Hepatitis C Drug Produces Huge Sales in Debut Quarter

Biz Break: Gilead's new hepatitis C drug produces huge sales in debut quarter
Gilead Sciences' revenues nearly doubled in one year thanks to the introduction of a breakthrough hepatitis C drug that produced more than $ 2 billion in sales in its debut quarter, the Foster City biopharmaceutical giant reported Tuesday. … in terms …
Read more on San Jose Mercury News

Principia's million readies cancer, autoimmune drugs for clinical trials
Building off technology licensed from the University of California, San Francisco, and experience honed at Genentech, Roche and other Bay Area biotech companies, Principia said its experimental small molecule drugs have antibody-like accuracy in …
Read more on Silicon Valley Business Journal

Safeguard Scientifics Announces First Quarter 2014 Financial Results
Collaborating with PerkinElmer will allow Good Start Genetics to reach more of the 60 million reproductive age women who are candidates for genetic carrier screening, ultimately helping to better assess their risks of, and options to avoid, having a …
Read more on Wall Street Journal

More Drug Treatment Options San Jose Information…